Sunday, October 26, 2025

Substantial U.S. health care spending continues to yield mixed results on system performance and health outcomes

China-origin assets accounted for an even larger share of big pharma licensing in Q1 2026

https://www.jpmorgan.com/content/dam/jpmorgan/documents/cb/insights/outlook/jpm-biopharma-deck-q1-2026.pdf